Review of breakpoints for ertapenem, imipenem, imipenem-relebactam, meropenem, meropenem-vaborbactam and ceftazidime-avibactam are ongoing. Following the second of two consultations, EUCAST will publish responses to comments received on the website shortly. The Steering Committee will continue to develop a new carbapenem breakpoint proposal for consultation later in 2026, with planned publication in v17.0 of the breakpoint tables.
